While there were few Grade 4 AEs, Lonial noted the treatment was well-tolerated among patients.
“It is pretty clear that we need to differentiate treatment of myeloma versus prevention of smoldering to developing myeloma. That treatment or prevention strategy is likely to be less intensive and may actually try to focus on enhancing immune surveillance of the existing malignant clone and preventing that clone from progressing, as opposed to eradication of the disease when you treat symptomatic myeloma,” he concluded.
Lidia Schapira, MD, FASCO, a breast cancer expert, associate professor of medicine at Stanford University School of Medicine, and director of cancer survivorship at the Stanford Comprehensive Cancer Institute, applauded the researchers for their findings and for identifying an unmet need in this patient population.
“It really covers an area that is a very important ASCO research priority, which is identifying strategies to actually detect and treat pre-malignant lesions,” she said. “This area of prevention rather than treatment is one where we have far too few successes and we really need to see more.”
Lonial S, Jacobus S, Fonseca R, et al. E3A06: Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma. Presented at: 2019 ASCO Annual Meeting Presscast; May 15. Abstract 8001.
<<< 2019 ASCO Annual Meeting